CasNo.19982-08-2,Memantine,Memantine(19982-08-2) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 98%
Payment Terms : T/T,

Keywords

19982-08-2 Memantine 3,5-Dimethyl-1-aminoadamantane

Quick Details

Appearance:offwhite solid
Application:19982-08-2 Memantine has been associated with a moderate decrease in clinical deterioration in Alzheimer's disease.A systematic review of randomised controlled trials found that memantine has a small
PackAge:1kg,5kg,10kg,25kg
ProductionCapacity:2|Metric Ton|Month
Storage:Store in dry, dark and ventilated place
Transportation:19982-08-2

Superiority:

Name		Memantine
Synonyms		1,3-Dimethylaminoadamantane; 3,5-Dimethyl-1-aminoadamantane; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine

Molecular Structure

Molecular Formula		C₁₂H₂₁N
Molecular Weight		179.30
CAS Registry Number		19982-08-2 (51052-62-1)

Properties

Density		1.046

Safety Data

Safety Description		S24/25 Details

Details:

Name		Memantine
Synonyms		1,3-Dimethylaminoadamantane; 3,5-Dimethyl-1-aminoadamantane; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine

Molecular Structure

Molecular Formula		C₁₂H₂₁N
Molecular Weight		179.30
CAS Registry Number		19982-08-2 (51052-62-1)

Properties

Density		1.046

Safety Data

Safety Description		S24/25 Details

MF: C₁₂H₂₁N
Density: 1.046 g/cm³
Flash Point: 92.3 °C
MW: 179.301840 g/mol
Product Name: Memantine
IUPAC: 3,5-dimethyladamantan-1-amine
Boiling Point: 239.8 °C at 760 mmHg
Enthalpy of Vaporization: 47.67 kJ/mol
Vapour Pressure: 0.0393 mmHg at 25°C
Synonyms: AKOS BB-9600 ; MEMANTINE ; AURORA KA-7643 ; TIMTEC-BB SBB002574 ; 3,5-dimethyladamantan-1-amine HCl ; 1-Amino-3,5-dimethyladamantane ; 3,5-Dimethyl-1-aminoadamantane ; 3,5-DIMETHYL-1-AMINOADAMANTANE( MEMANTINE )
Following is the molecular structure of Memantine (19982-08-2):

Memantine was first synthesized and patented by Eli Lilly and Company in 1968 (as cited in the Merck Index), and then developed by Merz in collaboration with Neurobiological Technologies, Inc. and licensed to Forest for the U.S. and Lundbeck for selected European and international markets.

Memantine has been associated with a moderate decrease in clinical deterioration in Alzheimer's disease.A systematic review of randomised controlled trials found that memantine has a small positive effect on cognition, mood, behaviour, and the ability to perform daily activities in moderate to severe Alzheimer's disease, but an unknown effect in mild to moderate disease.
Memantine is also being tested for opioid dependence, systemic lupus erythematosus, depression, obsessive compulsive disorder, Tourette Syndrome, problem gambling, attention-deficit hyperactivity disorder (ADHD),glaucoma, tinnitus, neuropathic pain including Complex Regional Pain Syndrome, pervasive developmental disorders, HIV associated dementia, nystagmus, and multiple sclerosis.

Safety Information of Memantine (19982-08-2):
Hazard Codes : Xi
Xi : Irritant
Safety Statements 24/25 ( Avoid contact with skin and eyes )
Hazardous Substances Data: 19982-08-2(Hazardous Substances Data)